secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001437749-24-000752
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics licenses Mayo Clinic's PSMA Alpha-PET platform for up to $68M milestones
--------------------------------------------------------------------------------

- Upfront cash payment of $1M due within 60 days of Dec 22, 2023; milestone payments up to $68M tied to clinical, regulatory, and commercialization achievements.
- Single-digit royalties on net sales of certain Licensed Product components; 40% of any PRV sale proceeds to be shared with Mayo.
- Platform uses 64/67 Cu and 203/212 Pb double chelator design for PET imaging and alpha/beta-particle targeted RPT.
- Preclinical data showed favorable salivary gland uptake and kidney clearance vs. comparators; initial focus on PSMA-expressing prostate cancer.
- Mayo Clinic holds financial interest in the technology; Perspective must use commercially reasonable efforts to bring Licensed Products to market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/0001437749-24-000752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/isr20240104_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-000752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer